“Financial Impacts of Waste, Fraud, and Abuse in Pharmaceutical Pricing: The goal of the hearing is to examine whether there are fraudulent, abusive, or wasteful pharmaceutical pricing practices that affect federal health programs such as Medicaid, Medicare, and the Public Health Service “340B” program that should be the subject of additional congressional oversight.” February 9, 2007.